Skip to main
KOD

KOD Stock Forecast & Price Target

KOD Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Kodiak Sciences Inc. has demonstrated significant advancements in its investigational medicines, particularly KSI-101, which has shown a strong efficacy profile with over 50% of patients experiencing a ≥3-line improvement in vision within four weeks and over 90% achieving retinal dryness by week eight. The recent positive results from the GLOW2 trial for tarcocimab tedromer have led to a substantial increase in the probability of success (POS) estimates for both diabetic retinopathy and wet age-related macular degeneration, highlighting the potential for these therapies to address unmet medical needs. Continued positive feedback from key opinion leaders regarding the ABC platform's innovations further enhances the outlook for Kodiak Sciences, supporting expectations for improved clinical outcomes and pivotal trial success in the near future.

Bears say

Kodiak Sciences Inc's outlook appears negative due to significant setbacks experienced by its original conjugated formulations, exemplified by the failures of the Phase 3 GLEAM and GLIMMER trials in diabetic macular edema (DME) and the Phase 2b/3 DAZZLE trial in wet age-related macular degeneration (AMD). Additionally, the company is facing substantial risks, including the possibility that its developmental candidates may not achieve the anticipated peak commercial revenue due to constraints related to market size, penetration rates, and pricing strategies. Another critical concern is the ongoing challenge of securing sufficient capital resources to fund operations and sustain program development and commercialization efforts.

KOD has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kodiak Sciences Inc (KOD) Forecast

Analysts have given KOD a Buy based on their latest research and market trends.

According to 7 analysts, KOD has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kodiak Sciences Inc (KOD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.